Search for a trial

A multicenter, prospective randomized study to compare vascular healing after deployment of the Abluminal Sirolimus Coated Bio-Engineered Stent (Combo Bio-Engineered Sirolimus Eluting Stent) versus the Everolimus Eluting Stent in patients with Acute Coronary Syndrome by means of Optical Coherence Tomography

See also page 19 (section 6) of the protocol:6. Study ObjectiveIt is the objective of this study to assess vascular healing by Optical Coherence Tomography (OCT) analysis after deployment of the Abluminal Sirolimus Coated Bio-Engineered Stent (Combo…

CLINICAL INVESTIGATION OF A DES (MISTENT* SYSTEM) WITH SIROLIMUS AND A BIOABSORBABLE POLYMER FOR THE TREATMENT OF PATIENTS WITH DE NOVO LESIONS IN NATIVE CORONARY ARTERIES

The primary objective of this study is to demonstrate whether the MiStent Drug Eluting Coronary Stent System can safely and effectively improve coronary luminal diameter in patients with symptomatic ischemic heart disease due to discrete de novo…

A RANDOMIZED, PARTIALLY-BLINDED, MULTI-CENTER, ACTIVE-CONTROLLED, DOSE
RANGING STUDY ASSESSING THE SAFETY, EFFICACY, AND PHARMACODYNAMICS OF THE
REG1 ANTICOAGULATION SYSTEM COMPARED TO UNFRACTIONATED HEPARIN OR LOW
MOLECULAR HEPARIN IN SUBJECTS WITH ACUTE CORONARY SYNDROME

To evaluate the safety and efficacy of the REG1 Anticoagulation System in Acute Coronary Syndrome patients undergoing cardiac catheterization by determination of the clinically acceptable dose range of RB007, which can be used to reliably reverse…

Prospective, multi-center, randomized, heparin-controlled dose-finding trial to evaluate the efficacy and safety of rivaroxaban, a direct factor Xa inhibitor, on the background of standard dual antiplatelet therapy to support elective percutaneous coronary intervention (X-Plorer).

The aim of this study is to assess whether rivaroxaban, as compared to UFH, on the background of standard dual antiplatelet therapy (DAPT), can effectively suppress thrombosis, and related adverse ischemic events, upon balloon inflation and stent…

Canyon-I-Pilot Trial a dose-ranging study of bolus-only Desirudin in patients undergoing PCI

The aim of this study is to find out if a percutaneous angioplasty can be carried out safely in patients who received a therapeutic dose of Desirudin (Revasc®) before the operation.

A Prospective, Randomized Study to Evaluate the Safety and Effectiveness of
an AbluMinal Sirolimus CoatED Bio-Engineered StEnt (Combo Bio-
Engineered Sirolimus Eluting Stent) Compared with a TAXUS® Liberté® Stent
Control Arm for Treatment of Stenotic Lesions in Native Coronary Arteries

The primary objective of this clinical trial is to demonstrate the safety and effectiveness of the Combo Bio-engineered Sirolimus Eluting Stent (Combo Stent) compared to the commercially available TAXUS® Liberté® Paclitaxel-Eluting Stent (DES) in…

Protect: Clinical evaluation of pacing during the onset of revascularization. Clinical feasibility study

The purpose of this study is to determine whether the application of ventricular pacing during PCI for AMI can protect the human heart from damage as a result of ischemia/reperfusion injury

Prospective, multi-center, randomized First-In-Man trial to compare the safety and efficacy of BuMA Supreme eG (Electro Grafting) based biodegradable polymer Sirolimus-eluting stent against Resolute Zotarolimus-eluting durable polymer stent in patients with de novo coronary artery lesions.

To evaluate the safety and effectiveness of the SINOMED BuMA Supreme Sirolimus-Eluting Coronary Stent System with biodegradable polymer versus the Medtronic Resolute Zotarolimus-Eluting Coronary Stent System through angiographic and clinical…